Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Thursday’s White-Hot Stocks: Evoke Pharma, GrubHub, Logitech, More

Page 1 of 2

Stocks are wavering on Thursday following a rise in weekly jobless claims, a widening trade deficit, and mixed earnings reports. However, some stocks are having big days on positive earnings results and other news, including Evoke Pharma Inc (NASDAQ:EVOK), GrubHub Inc (NYSE:GRUB), ARRIS International plc (NASDAQ:ARRS), Ocwen Financial Corp (NYSE:OCN), and Logitech International SA (USA) (NASDAQ:LOGI). Let’s find out why these stocks are gaining value today and also see what the hedge funds tracked by us think of these companies.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).

stock, exchange, trade, ipo, market, london, share, rate, sales, price, new, york, profit, index, broker, chart, rising, falling, street, frankfurt, wall, world, cash, points, display,

lassedesignen/Shutterstock.com

FDA Conditionally Accepts Evoke Pharma’s Gimoti Brand Name

Evoke Pharma Inc (NASDAQ:EVOK) has skyrocketed by more than 26% so far today following the FDA’s conditional acceptance of the proposed brand name ‘Gimoti’ for the company’s metoclopramide nasal spray EVK-001. According to a statement released by the California-based specialty pharmaceutical company, a request for proprietary name review for Gimoti will be included when the company submits a New Drug Application (NDA) for the product candidate, which the company believes there is value in pursuing. Evoke’s CEO Dave Gonyer said that the company is analyzing data from its recently completed Phase 3 trial EVK-001 and considering all submission strategies. Just three funds in our database were bullish on Evoke Pharma Inc (NASDAQ:EVOK) at the end of the first quarter.

Follow Evoke Pharma Inc (NASDAQ:EVOK)
Trade (NASDAQ:EVOK) Now!

GrubHub Beats Estimates

GrubHub Inc (NYSE:GRUB)’s stock is going through the roof today, gaining 22.06% so far after the company beat analysts’ forecasts with its second quarter earnings. The New York-headquartered online- and mobile-based food ordering company earned $0.23 per share, better than the consensus estimate of $0.19. Revenue of $120.20 million also surpassed the consensus estimate of $114.13 million. Active diners rose by 24% year-over-year to 7.35 million during the quarter. For the full year, GrubHub expects revenue of $480 million-to-$488 million, higher than the estimates of $473.3 million. 23 hedge funds out of the 766 active funds tracked by Insider Monkey were long GrubHub Inc (NYSE:GRUB) at the end of March.

Follow Grubhub Inc. (NYSE:GRUB)
Trade (NYSE:GRUB) Now!

On the next page we’ll discuss why ARRIS, Ocwen Financial, and Logitech are making big upward moves today.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!